Recursion

About

What began in 2013 as an idea stemming from the doctoral work of Chris Gibson, alongside co-founders Dr. Dean Li and Blake Borgeson, has blossomed into Recursion Pharmaceuticals, a clinical-stage TechBio company at the forefront of revolutionizing drug discovery. Initially operating out of a small lab in Salt Lake City, Utah, the company was founded with a vision to merge experimental biology, automation, and artificial intelligence to decode biology and radically improve lives. The core concept was to leverage technology to navigate the immense complexity of biology and chemistry, aiming to make the process of finding new medicines faster, more efficient, and ultimately more successful. Recursion's journey has been marked by significant technological advancements and strategic growth. The company developed the Recursion Operating System (OS), a sophisticated platform that integrates diverse technologies to generate and analyze one of the world's largest proprietary biological and chemical datasets. This OS enables Recursion to conduct millions of wet-lab experiments weekly, utilizing machine learning algorithms to identify trillions of searchable relationships across biology and chemistry, often unconstrained by existing human knowledge. This data-first approach allows for the validation of unbiased discoveries in traditional lab settings, creating a virtuous cycle of continuous learning. Headquartered in Salt Lake City, Utah, Recursion has expanded its presence with offices in London, Toronto, Montreal, and Milpitas, California, reflecting its growth into a multinational entity. The company has also forged significant partnerships with major pharmaceutical companies like Bayer, Roche/Genentech, and Sanofi, and has attracted investment from notable entities including Nvidia. With a commitment to its core values of caring, learning, delivering, acting boldly with integrity, and being one unified team, Recursion continues its mission to industrialize drug discovery and bring transformative therapies to patients facing a multitude of diseases.